Search

everythinglearnresearchcommunity

for

Search:↓

PDE inhibitors, especially PDE4 inhibitors like apremilast, are effective for certain inflammatory skin conditions but have side effects and can be costly.

New treatments like nanotechnology show promise in improving skin cancer therapy.

Tofacitinib, a JAK inhibitor, improved hair regrowth in most patients with severe alopecia areata and had minimal side effects.

Baricitinib for severe alopecia areata is generally safe, with common side effects like infections and acne, and low rates of serious complications.

Case-only trees and random forests improve predictions of treatment effects in clinical trials.

The enzymes 5α-reductase and 3α/β-hydroxysteroid oxidoreductase help create brain-active substances from progesterone and testosterone, which could be used for treatment, but more research is needed to ensure their safety and effectiveness.

The flexible fixed-sequence testing method allows for more effective evaluation of multiple goals in a clinical trial while controlling the risk of false positives.

Samcyprone ointment is effective for treating common warts if a sensitization reaction occurs first.

Bendamustine, often combined with other drugs, is effective and less toxic for certain blood cancers, but less effective for young, fit patients with CLL.

Oral tofacitinib significantly improves lichen planopilaris symptoms without adverse effects.

Continuous baricitinib is needed to keep hair regrowth in severe alopecia areata.

The study helps doctors use patient images to understand and apply SALT scores for treating severe alopecia areata.

Patients with severe alopecia areata felt better and less anxious or depressed when treated with baricitinib compared to placebo.

Oral JAK inhibitors are effective and safe for treating alopecia areata but may need ongoing use to keep results.

Proxalutamide improved recovery, lowered death rates, and reduced hospital stay for COVID-19 patients.

Teriflunomide is safe and tolerable for treating relapsing-remitting multiple sclerosis, with manageable side effects.

Some treatments for severe hair loss work but often have side effects, with baricitinib showing the most promise.

New treatments targeting immune pathways show promise for severe hair loss but need more research for safety and effectiveness.

Tofacitinib helped regrow hair in patients with alopecia, with few side effects.

Dupilumab is being tested for many new skin, respiratory, and gastrointestinal conditions.

Teriflunomide is an effective and generally safe oral treatment for relapsing MS, reducing relapses and slowing disability progression.

The Li-Pa/Ca and Do/Ca chemotherapy regimens for serous ovarian cancer showed better short-term and long-term results than the Pa/Ca regimen.

Certain HSD3B1 gene types are linked to worse prostate cancer outcomes and affect treatment response and other health conditions.

Oral baricitinib and ruxolitinib are effective and safe for treating alopecia areata.

Proactive monitoring and management are essential to maximize the benefits of Trastuzumab Deruxtecan while minimizing serious side effects.

A woman with a type of hair loss saw hair regrowth after two months of taking baricitinib.

Eyebrow hair transplants in patients with frontal fibrosing alopecia may look good at first but often lose the new hair after a few years.

Teriflunomide helps reduce multiple sclerosis symptoms and is safe for most patients.

Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.

The guidelines suggest a detailed approach to diagnosing and treating lupus, with a focus on regular check-ups, personalized medicine, and a range of drug options for different cases.